Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HL-1186 in Healthy Participants
NCT06912295Phase 1Recruiting
- Sponsor
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
- Start
- Mar 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in diabetic polyneuropathy (DPN) and postoperative pain comparing HL-1186 with Placebo (2 arms). Primary endpoint: Safety and Tolerability. Started Mar 2025; status: recruiting.
02
Drugs
HL-1186
03
Conditions
diabetic polyneuropathy (DPN)postoperative pain
Beyond the preview
Go deeper on NCT06912295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06912295.